Blog Blog1

I. Early August: Accelerated Pace of Innovative Drug Approvals

Entering August, the pace of innovative drug approvals in China is visibly accelerating.

On August 6, Nanjing Yateng Pharmaceutical's independently developed multi-target kinase inhibitor Jieentai® (tinengotinib tablets) received NMPA approval for the treatment of adult patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and FGFR inhibitor therapy. This is the first Class 1 innovative drug from a Nanjing-based pharmaceutical company.

On August 7, Hengrui Medicine announced NMPA approval for its independently developed Class 1 innovative drug, ivarmacitinib sulfate tablets. On the same day, Sino Biopharmaceutical announced that its subsidiary Chia Tai Tianqing received NMPA approval for a new indication of its independently developed Class 1 innovative drug, benmelstobart injection——for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer. Shandong Lukang Pharmaceutical also received registration certificates for two drugs on the same day: brexpiprazole tablets and lenvatinib mesylate capsules.

On August 10, Hengrui's HER2 ADC innovative drug Aivita® (recombinant anti-HER2 ADC) received NMPA approval for a new indication——for the treatment of colorectal cancer after oxaliplatin-based therapy. This is the first anti-HER2 product approved for colorectal cancer in China and the third indication for Aivita®.

Additionally, the Class 1 innovative drug estavir tablets (aipusiwei®), jointly developed by Westlake University, Westlake Laboratory, and Westlake Pharma, was also recently approved for the treatment of mild COVID-19 in adults.

II. AI Pharma Financing Continues to Heat Up, Clinical Progress Accelerates

The AI pharma sector is also releasing a dense wave of signals in August.

On August 5, Beijing Zheyuan Technology announced the completion of a nearly RMB 200 million Series A2 financing round, with funds to be used for AI4S platform upgrades and global asset development. On August 10, AI pharma and virtual cell innovation company DeepCell announced the completion of a nearly RMB 100 million seed round, co-led by CAS Star, Shunxi Fund, and Cenova Capital.

The bigger picture: since the beginning of 2026, Insilico Medicine has reached 10 out-licensing and partnership deals, with total transaction scale approaching $10 billion. In July 2026, Insilico announced a strategic collaboration with Kangzhe Pharma for CNS drug discovery, with milestone payments up to approximately RMB 1.2 billion. Its lead pipeline Rentosertib initiated Phase III in July, with key data expected in 2027-2028.

Meanwhile, J-Tech reached a $1.6 billion partnership with Deerfield, and XtalPi received its second $19 million milestone payment from a platform collaboration. The industry is moving from "can AI make drugs" to the critical validation phase of "can AI-made drugs deliver value."

III. GLP-1 Pipeline Continues to Deliver New Data

The GLP-1 space has also seen multiple noteworthy research developments recently.

On August 4, Hengrui announced positive topline results from its Phase III trial of the GLP-1/GIP dual agonist reperptide injection in Chinese type 2 diabetes patients. On August 7, Eli Lilly's retatrutide 12 mg dose achieved 23% weight loss in a Phase III study (vs 3% for placebo).

On August 9, at the 2026 China Obesity Congress, Pfizer's next-generation biased GLP-1 receptor agonist ecnoglutide presented multiple post-hoc analyses from the SLIMMER studies. At 48 weeks, the 1.2 mg, 1.8 mg, and 2.4 mg groups achieved mean weight reductions of 11.7%, 14.6%, and 18.3%, respectively.

Additionally, a large real-world study published on August 10 in Annals of Oncology, involving over 160,000 subjects, showed that GLP-1 use in non-diabetic obese populations was significantly associated with a 41% reduction in risk for 13 obesity-related cancers——a finding that may further expand the application boundaries of GLP-1 drugs.

IV. BD Out-licensing and CXO Earnings Continue to Validate Industry Momentum

On the BD front, Chinese innovative drug companies disclosed 123 BD transactions in H1 2026, up 24.24% year-over-year, with total upfront payments exceeding $4.975 billion, up 71.65% year-over-year. On August 4, Kangning Jerry announced a licensing agreement with U.S. AI pharma Pathos AI, granting overseas rights to JSKN016, a first-in-class TROP2/HER3 bispecific ADC, with a total potential deal value exceeding $2.2 billion.

The CXO sector is validating the same trend. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with net profit of RMB 11.57 billion, up 83.2% year-over-year, and backlog of RMB 66.43 billion as of June-end, up 25.2% year-over-year. Joinn Laboratories expects H1 net profit growth of 884.9%-1377.4% year-over-year. A China Securities research report showed that global innovative drug financing in H1 2026 reached $20.177 billion, with domestic financing of $4.233 billion——already 82% of the full-year 2025 total.

V. Multiple Factors Converging, Driving Upstream Custom Synthesis Demand

The series of events in early August——accelerated innovative drug approvals, continued AI pharma financing momentum, emerging GLP-1 data, and sustained BD out-licensing and CXO earnings validation——together point to one signal: the multiple drivers of the innovative drug industry are firing simultaneously.

More innovative drugs entering clinical and commercial stages translate into sustained demand for high-purity intermediates, chiral building blocks, and complex heterocyclic compounds. As AI pharma moves from concept to clinical validation, the new targets and molecules identified by AI ultimately need to return to the lab——they require real compounds for validation.

VI. Beixinke Chem's Perspective

As a custom synthesis service provider based in Shanghai, specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, Beixinke Chem is witnessing the real-world transmission of this multi-factor industry shift upstream.

From our front-line experience: since the beginning of 2026, we have seen a noticeable increase in inquiries for new product development. Compared to 2025, demand for custom synthesis from labs and research organizations is accelerating——with requirements that are more specific, more concrete, and more urgent.

Our core capabilities cover the entire chain from retrosynthetic analysis to process scale-up: chiral construction, heterocyclic assembly, milligram-to-kilogram scale-up, and full HPLC/LC-MS/NMR analytical support. We have provided custom synthesis support to R&D labs and biotech companies both in China and internationally——across different scales and requirements.

If your R&D team is also tracking what this industry shift means for your supply chain, we would welcome the conversation.